Amyloid Imaging–Based Food and Drug Administration Approval of Lecanemab to Treat Alzheimer Disease—What Lasts Long Finally Becomes Good?

![Figure][1] Henryk Barthel Alzheimer disease (AD) is a devastating neurologic condition of high socioeconomic relevance. Although today this disease can be accurately diagnosed during a lifetime, especially with the help of molecular imaging approaches such as amyloid PET, tau PET or 18F-